Detection of human papillomavirus DNA and p53 codon 72 polymorphism in prostate carcinomas of patients from Argentina

Springer Science and Business Media LLC - Tập 5 Số 1 - 2005
Gustavo José Leirós1, Silvia Galliano1, Mario Eduardo Sember2, Tomas Kahn3, Elisabeth Schwarz3, Kumiko Eiguchi1
1Catedra de Bioquimica e Inmunologia, Facultad de Medicina-Universidad del Salvador, Buenos Aires, Argentina
2Servicio de patología, Hospital Israelita, Buenos Aires, Argentina
3Deutsches Krebsforschungszentrum, Heidelberg, Germany

Tóm tắt

Abstract Background

Infections with high-risk human papillomaviruses (HPVs), causatively linked to cervical cancer, might also play a role in the development of prostate cancer. Furthermore, the polymorphism at codon 72 (encoding either arginine or proline) of the p53 tumor-suppressor gene is discussed as a possible determinant for cancer risk. The HPV E6 oncoprotein induces degradation of the p53 protein. The aim of this study was to analyse prostate carcinomas and hyperplasias of patients from Argentina for the presence of HPV DNA and the p53 codon 72 polymorphism genotype.

 Methods

HPV DNA detection and typing were done by consensus L1 and type-specific PCR assays, respectively, and Southern blot hybridizations. Genotyping of p53 codon 72 polymorphism was performed both by allele specific primer PCRs and PCR-RFLP (Bsh1236I). Fischer's test with Woolf's approximation was used for statistical analysis.

 Results

HPV DNA was detected in 17 out of 41 (41.5 %) carcinoma samples, whereas all 30 hyperplasia samples were HPV-negative. Differences in p53 codon 72 allelic frequencies were not observed, neither between carcinomas and hyperplasias nor between HPV-positive and HPV-negative carcinomas.

 Conclusion

These results indicate that the p53 genotype is probably not a risk factor for prostate cancer, and that HPV infections could be associated with at least a subset of prostate carcinomas.

Từ khóa


Tài liệu tham khảo

Ruijter E, van de Kaa C, Miller G, Ruiter D, Debruyne F, Schalken J: Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev. 1999, 20: 22-45. 10.1210/er.20.1.22.

zur Hausen H: Papillomaviruses causing cancer: Evasion from host cell control in early events in carcinogenesis. J Natl Cancer Inst. 2000, 92: 690-698. 10.1093/jnci/92.9.690.

Key T: Risk factors for prostate cancer. Cancer Surv. 1995, 23: 63-77.

Moyret-Lalle C, Marcais C, Jacquemier J, Moles JP, Daver A, Soret JY, Jeanteur P, Ozturk M, Theillet C: Ra s, p53 and HPV status in benign and malignant prostate tumors. Int J Cancer. 1995, 64: 124-129.

Cuzick J: Human papillomavirus infection of the prostate. Cancer Surv. 1995, 23: 91-95.

Strickler HD, Burk R, Shah K, Viscidi R, Jakcson A, Pizza G, Bertoni F, Schiller JT, Manns A, Metcalf R, Qu W, Goedert JJ: A multifaceted study of human papillomavirus and prostate carcinoma. Cancer. 1998, 82: 1118-1125. 10.1002/(SICI)1097-0142(19980315)82:6<1118::AID-CNCR16>3.0.CO;2-9.

Thomas M, Pim D, Banks L: The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene. 1999, 18: 7690-7700. 10.1038/sj.onc.1202953.

Münger K, Basile JR, Duensing S, Eichten A, Gonzalez SL, Grace M, Zacny VL: Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene. 2001, 20: 7888-7898. 10.1038/sj.onc.1204860.

Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV: Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol. 1987, 7: 961-963.

Storey A, Thomas M, Kalita A, Harwwod C, Gardiol D, Mantovani F, Brever J, Leight IM, Matlashewski G, Banks L: Role of p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998, 393: 229-234. 10.1038/30400.

Zehbe I, Voglino G, Wilander E, Delius H, Marongiu A, Edler L, Klimek F, Andersson S, Tomamasino M: P53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development. Cancer Res. 2001, 61: 608-611.

Malcolm EK, Baber GB, Boyd JC, Stoler MH: Polymorphism at codon 72 of p53 is not associated with cervical cancer risk. Mod Pathol. 2000, 13: 373-378. 10.1038/modpathol.3880061.

Henner WD, Evans AJ, Hough KM, Harris EL, Lowe BA, Beer TM: Association of codon 72 polymorphism of p53 with lower prostate cancer risk. Prostate. 2001, 49: 263-266. 10.1002/pros.10021.

Hoffmann M, Kahn T, Mahnke CG, Goeroegh T, Lippert BM, Werner JA: Prevalence of human papillomavirus in squamous cell carcinoma of the head and neck determined by polymerase chain reaction and southern blot hybridization: Proposal for optimized diagnostic requirements. Acta Otolaryngol (Stockh). 1998, 118: 138-144.

Grussendorf-Conen E, Deutz FJ, de Villiers EM: Detection of human papillomavirus-6 in primary carcinoma of the urethra in men. Cancer. 1987, 60: 1832-1835.

Mevorach RA, Cos LR, di Sant Agnese PA, Stoler M: Human papillomavirus type 6 in grade I transitional cell carcinoma of the urethra. J Urol. 1990, 143: 126-128.

Scholefield JH, Hickson WG, Smith JH, Rogers K, Sharp F: Anal intraepithelial neoplasia: part of a multifocal disease process. Lancet. 1992, 340: 1271-1273. 10.1016/0140-6736(92)92961-E.

Beckmann AM, Daling JR, Sherman KJ, Maden C, Miller BA, Coates RJ, Kiviat NB, Myerson D, Weiss NS, Hislop TG: Human papilomavirus infection and anal cancer. Int J Cancer. 1989, 43: 1042-1049.

Serth J, Panitz F, Paeslack U, Kuczyk MA, Jonas U: Increased levels of human papillomavirus type 16 DNA in a subset of prostate cancers. Cancer Res. 1999, 59: 823-825.

Noda T, Sasagawa T, Dong Y, Fuse H, Namiki M, Inoue M: Detection of human papillomavirus (HPV) DNA in archival specimens of benign prostatic hyperplasia and prostatic cancer using a highly sensitive nested PCR method. Urol Res. 1998, 26: 165-169. 10.1007/s002400050041.

Saad F, Gu K, Jean-Baptiste J, Gauthier J, Mesmasson AM: Absence of human papillomavirus sequences in early stage prostate cancer. Can J Urol. 1999, 6: 834-838.

Rosenthal A, Ryan A, Al-Jehani RM, Storey A, Harwood CA, Jacobs IJ: p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet. 1998, 352: 871-872. 10.1016/S0140-6736(98)07357-7.

Josefsson A, Magnusson PK, Ylitalo N, Magnusson P, Ylitalo N, Quarforth-Tubbin P, Ponten J, Adami H, Gyllensten U: p53 polymorphism and risk of cervical cancer. Nature. 1998, 396: 531-532. 10.1038/25037.

Giannoudis A, Graham DA, Southern SA, Herrington CS: P53 codon 72 Arg/Pro polymorphism is not related to HPV type or lesion grade in low- and high- grade squamous intra-epithelial lesions and invasive squamous carcinoma of the cervix. Int J Cancer. 1999, 83: 66-69. 10.1002/(SICI)1097-0215(19990924)83:1<66::AID-IJC13>3.0.CO;2-K.

Zehbe I, Voglino G, Wilander E, Genta F, Tommasino M: Codon 72 polymorphism of p53 and its association with cervical cancer. Lancet. 1999, 354: 218-219. 10.1016/S0140-6736(99)01914-5.

Szarka K, Veress G, Juhasz A, Konya J, Sapy T, Soos G, Hernadi Z, Gergely L: Integration status of virus DNA and p53 codon 72 polymorphism in human papillomavirus type 16 positive cervical cancers. Anticancer Res. 2000, 20: 2161-2167.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 5 Số 1

Thông tin tác giả